HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy

Timothy R. Sterling, Richard E Chaisson, Richard D Moore

Research output: Contribution to journalArticle

Abstract

Objective: To determine if HIV-1 RNA and CD4 lymphocyte thresholds for the initiation of highly active antiretroviral therapy (HAART) are associated with clinical response to therapy. Design: Observational cohort study. Setting: Johns Hopkins Hospital HIV Clinic. Patients: HIV-infected adults. Intervention: Patients initiating HAART (n = 530) were compared with concurrent patients who did not receive HAART (n = 484). Main outcome measure: Progression to a new AIDS-defining illness or death. Results: The average duration of follow-up for the cohort was 22 months. HAART resulted in decreased disease progression among persons with fewer than, but not more than, 200 × 106 CD4 lymphocytes/l prior to treatment. Among persons receiving HAART, plasma HIV-1 RNA level prior to therapy was not associated with HIV disease progression within CD4 T-lymphocyte count strata. In a Cox multivariate proportional hazards model that adjusted for age, sex, race, prior opportunistic infection, and CD4 T lymphocytes, ≤ 200 × 106 CD4 lymphocytes/l was the strongest predictor of disease progression. HIV-1 RNA level prior to starting HAART of <5000 copies/ml, 5001-55 000 copies/ml, or > 55 000 copies/ml was not associated with disease progression on therapy, particularly among persons with > 200 × 106 CD4 lymphocytes/l. There was no sex difference in disease progression on treatment. Conclusions: Our data suggest that current guidelines for initiating HAART should place greater emphasis on CD4 lymphocyte than HIV-1 RNA level for both men and women. Further longitudinal follow-up will be needed to better ascertain whether HAART initiated at > 200 × 106 CD4 lymphocytes/l is effective in slowing disease progression.

Original languageEnglish (US)
Pages (from-to)2251-2257
Number of pages7
JournalAIDS
Volume15
Issue number17
DOIs
StatePublished - Nov 23 2001

Fingerprint

Highly Active Antiretroviral Therapy
HIV-1
RNA
T-Lymphocytes
Disease Progression
Lymphocytes
HIV
Therapeutics
Opportunistic Infections
CD4 Lymphocyte Count
Proportional Hazards Models
Sex Characteristics
Observational Studies
Acquired Immunodeficiency Syndrome
Cohort Studies
Outcome Assessment (Health Care)
Guidelines

Keywords

  • AIDS
  • Antiretroviral therapy
  • CD4 cells
  • HIV-1
  • HIV-1 RNA
  • Plasma viral load

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. / Sterling, Timothy R.; Chaisson, Richard E; Moore, Richard D.

In: AIDS, Vol. 15, No. 17, 23.11.2001, p. 2251-2257.

Research output: Contribution to journalArticle

@article{7455e9aec4174d40b11ee072701bfd61,
title = "HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy",
abstract = "Objective: To determine if HIV-1 RNA and CD4 lymphocyte thresholds for the initiation of highly active antiretroviral therapy (HAART) are associated with clinical response to therapy. Design: Observational cohort study. Setting: Johns Hopkins Hospital HIV Clinic. Patients: HIV-infected adults. Intervention: Patients initiating HAART (n = 530) were compared with concurrent patients who did not receive HAART (n = 484). Main outcome measure: Progression to a new AIDS-defining illness or death. Results: The average duration of follow-up for the cohort was 22 months. HAART resulted in decreased disease progression among persons with fewer than, but not more than, 200 × 106 CD4 lymphocytes/l prior to treatment. Among persons receiving HAART, plasma HIV-1 RNA level prior to therapy was not associated with HIV disease progression within CD4 T-lymphocyte count strata. In a Cox multivariate proportional hazards model that adjusted for age, sex, race, prior opportunistic infection, and CD4 T lymphocytes, ≤ 200 × 106 CD4 lymphocytes/l was the strongest predictor of disease progression. HIV-1 RNA level prior to starting HAART of <5000 copies/ml, 5001-55 000 copies/ml, or > 55 000 copies/ml was not associated with disease progression on therapy, particularly among persons with > 200 × 106 CD4 lymphocytes/l. There was no sex difference in disease progression on treatment. Conclusions: Our data suggest that current guidelines for initiating HAART should place greater emphasis on CD4 lymphocyte than HIV-1 RNA level for both men and women. Further longitudinal follow-up will be needed to better ascertain whether HAART initiated at > 200 × 106 CD4 lymphocytes/l is effective in slowing disease progression.",
keywords = "AIDS, Antiretroviral therapy, CD4 cells, HIV-1, HIV-1 RNA, Plasma viral load",
author = "Sterling, {Timothy R.} and Chaisson, {Richard E} and Moore, {Richard D}",
year = "2001",
month = "11",
day = "23",
doi = "10.1097/00002030-200111230-00006",
language = "English (US)",
volume = "15",
pages = "2251--2257",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "17",

}

TY - JOUR

T1 - HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy

AU - Sterling, Timothy R.

AU - Chaisson, Richard E

AU - Moore, Richard D

PY - 2001/11/23

Y1 - 2001/11/23

N2 - Objective: To determine if HIV-1 RNA and CD4 lymphocyte thresholds for the initiation of highly active antiretroviral therapy (HAART) are associated with clinical response to therapy. Design: Observational cohort study. Setting: Johns Hopkins Hospital HIV Clinic. Patients: HIV-infected adults. Intervention: Patients initiating HAART (n = 530) were compared with concurrent patients who did not receive HAART (n = 484). Main outcome measure: Progression to a new AIDS-defining illness or death. Results: The average duration of follow-up for the cohort was 22 months. HAART resulted in decreased disease progression among persons with fewer than, but not more than, 200 × 106 CD4 lymphocytes/l prior to treatment. Among persons receiving HAART, plasma HIV-1 RNA level prior to therapy was not associated with HIV disease progression within CD4 T-lymphocyte count strata. In a Cox multivariate proportional hazards model that adjusted for age, sex, race, prior opportunistic infection, and CD4 T lymphocytes, ≤ 200 × 106 CD4 lymphocytes/l was the strongest predictor of disease progression. HIV-1 RNA level prior to starting HAART of <5000 copies/ml, 5001-55 000 copies/ml, or > 55 000 copies/ml was not associated with disease progression on therapy, particularly among persons with > 200 × 106 CD4 lymphocytes/l. There was no sex difference in disease progression on treatment. Conclusions: Our data suggest that current guidelines for initiating HAART should place greater emphasis on CD4 lymphocyte than HIV-1 RNA level for both men and women. Further longitudinal follow-up will be needed to better ascertain whether HAART initiated at > 200 × 106 CD4 lymphocytes/l is effective in slowing disease progression.

AB - Objective: To determine if HIV-1 RNA and CD4 lymphocyte thresholds for the initiation of highly active antiretroviral therapy (HAART) are associated with clinical response to therapy. Design: Observational cohort study. Setting: Johns Hopkins Hospital HIV Clinic. Patients: HIV-infected adults. Intervention: Patients initiating HAART (n = 530) were compared with concurrent patients who did not receive HAART (n = 484). Main outcome measure: Progression to a new AIDS-defining illness or death. Results: The average duration of follow-up for the cohort was 22 months. HAART resulted in decreased disease progression among persons with fewer than, but not more than, 200 × 106 CD4 lymphocytes/l prior to treatment. Among persons receiving HAART, plasma HIV-1 RNA level prior to therapy was not associated with HIV disease progression within CD4 T-lymphocyte count strata. In a Cox multivariate proportional hazards model that adjusted for age, sex, race, prior opportunistic infection, and CD4 T lymphocytes, ≤ 200 × 106 CD4 lymphocytes/l was the strongest predictor of disease progression. HIV-1 RNA level prior to starting HAART of <5000 copies/ml, 5001-55 000 copies/ml, or > 55 000 copies/ml was not associated with disease progression on therapy, particularly among persons with > 200 × 106 CD4 lymphocytes/l. There was no sex difference in disease progression on treatment. Conclusions: Our data suggest that current guidelines for initiating HAART should place greater emphasis on CD4 lymphocyte than HIV-1 RNA level for both men and women. Further longitudinal follow-up will be needed to better ascertain whether HAART initiated at > 200 × 106 CD4 lymphocytes/l is effective in slowing disease progression.

KW - AIDS

KW - Antiretroviral therapy

KW - CD4 cells

KW - HIV-1

KW - HIV-1 RNA

KW - Plasma viral load

UR - http://www.scopus.com/inward/record.url?scp=0035941382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035941382&partnerID=8YFLogxK

U2 - 10.1097/00002030-200111230-00006

DO - 10.1097/00002030-200111230-00006

M3 - Article

C2 - 11698698

AN - SCOPUS:0035941382

VL - 15

SP - 2251

EP - 2257

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 17

ER -